Prescribing Trazodone

Why Trazodone Still Matters

Trazodone is one of the most-prescribed psychiatric medications in the United States, and almost nobody prescribes it for what the FDA approved it to do. Licensed in 1981 as an antidepressant, it long ago migrated into a second life as America's default off-label hypnotic: a cheap, non-scheduled, non-addictive sleeping pill that costs roughly three cents a dose. That migration is not an accident of marketing. It reflects a real and useful pharmacology: at low doses trazodone is a potent H1 and 5-HT2A antagonist that produces sleep, and unlike benzodiazepines and z-drugs it improves sleep architecture rather than degrading it.

The drug's reputation suffers from two opposite distortions. Sleep specialists sometimes dismiss it because the randomized primary-insomnia database is thin (there was never a sponsor with an incentive to build one; it went generic decades ago). Meanwhile clinicians who reach for it reflexively at 50 mg qhs often forget it is a genuine antidepressant with a genuine side-effect profile: orthostatic hypotension, next-day sedation, a rare but real risk of priapism, and an active metabolite (mCPP) that can cause trouble when the wrong CYP2D6 inhibitor is layered on top.

This guide covers both trazodones: the sedating adjunct used nightly for insomnia, and the full-dose antidepressant most clinicians have never actually titrated because they can't get patients past the sedation.

Part 1: Indications: Who Is Trazodone For?

FDA-Approved

• Major depressive disorder (the only on-label use)

The paradox is that trazodone is rarely used at true antidepressant doses (300 to 400 mg/day), because the sedation that makes it an excellent hypnotic makes full-dose monotherapy hard to tolerate. Head-to-head meta-analyses rank it among the less efficacious and less acceptable antidepressants (higher dropout, largely from sedation), not because it doesn't work, but because patients quit before reaching an effective dose. It is best thought of as a second- or third-line antidepressant: worth a trial after the top two choices fail, particularly when insomnia, agitation, or a desire to avoid weight gain and sexual side effects dominates the picture.

The Evidence-Based Off-Label Uses

Primary and secondary insomnia: the real reason it's on your formulary. This is trazodone's home turf. At 25 to 150 mg qhs it increases total sleep time by roughly 30 to 50 minutes and, critically, does so while increasing slow-wave (deep, stage 3) sleep rather than suppressing it the way benzodiazepines and z-drugs do. It works for initial, middle, and terminal insomnia. It is especially valuable for insomnia secondary to depression, where a low nightly dose can be layered onto an activating antidepressant (an SSRI or bupropion) to rescue sleep without adding a second full-dose drug.

Sleep disturbance and nightmares in PTSD. The VA uses trazodone as a first-line option for sleep and nightmares in PTSD, driven by its safety, non-addictiveness, and coverage of behavioral symptoms.

Behavioral and psychological symptoms of dementia (BPSD). Useful adjunctively for agitation and insomnia in dementia, with a signal for particular benefit in frontotemporal dementia. Typical dementia dosing runs around 50 to 100 mg/day (mean about 100 mg/day, range 50 to 300). It does not improve cognition or slow decline: a UK cohort (n≈2,199) found no MMSE benefit versus citalopram or mirtazapine, but it manages the behavioral symptoms with acceptable tolerability, and it avoids the mortality signal of antipsychotics in this population.

Antipsychotic-induced akathisia. As a 5-HT2A antagonist, trazodone 50 to 100 mg qhs reduced akathisia in a small placebo-controlled trial. A reasonable adjunct alongside propranolol and mirtazapine when a dose reduction or benzodiazepine isn't enough.

Generalized anxiety disorder. In the classic Rickels RCT (1993), trazodone (about 225 mg/day) beat placebo but underperformed imipramine. It is not a first-line anxiolytic, but the sedating profile can help anxious, insomniac patients.

Insomnia in TBI and schizophrenia. 50 to 200 mg qhs, after behavioral approaches, when a non-addictive sleep agent is wanted.

Where the Evidence Is Weak or Absent

• Panic disorder, OCD: little evidence; don't reach for trazodone here.
• SSRI-induced sexual dysfunction: the "add trazodone to reverse it" strategy rests on one tiny open-label trial and is likely placebo; don't rely on it.
• Neuroprotection / dementia prevention: mouse models hint at reversal of protein aggregation, but there is no human evidence that trazodone preserves cognition or reduces dementia incidence. Do not use it for that purpose.

Who Is a Good Candidate?

• Patients with insomnia, primary, or secondary to depression, PTSD, or dementia
• Patients you want to keep off scheduled hypnotics (history of substance use, older adults, anyone where dependence is a concern)
• Depressed patients where avoiding weight gain and sexual dysfunction is a priority
• Depressed patients already taking trazodone for sleep, in whom you can climb to an antidepressant dose rather than adding a second drug

Who Is a Poor Candidate?

• Patients at high risk of hypotensive falls (frail elderly, autonomic dysfunction, existing orthostasis)
• Patients with significant cardiac disease (orthostasis, QT)
• Depressed patients whose picture is dominated by fatigue and hypersomnia, where sedation works against you
• Men with a history of priapism, or patients with sickle cell / vaso-occlusive disease

Part 2: Before You Start: Workup and Candidacy

Trazodone requires far less pre-work than lithium. There are no mandatory baseline labs and no serum-level monitoring. What you owe every patient is a short, targeted history and, in selected patients, an ECG.

At Baseline

• Cardiac and orthostatic screen. Ask about known cardiac disease, syncope, dizziness on standing, and falls. Check a baseline blood pressure, ideally with orthostatics, especially in older or frail patients.
• Priapism risk in men. Ask briefly about erectile history and any prior prolonged or painful erections. A prior priapism episode is a relative contraindication.
• Medication reconciliation for interactions. Specifically scan for CYP3A4 inhibitors (which raise trazodone levels, driving sedation and QT effects) and CYP2D6 inhibitors (which raise mCPP, driving dysphoria and anxiety). See Part 7.

Consider a Baseline (and Periodic) ECG If:

• Age 65 or older
• Known cardiovascular disease or prior arrhythmia
• Co-prescribed a CYP3A4 inhibitor or another QT-prolonging drug (e.g., methadone, ziprasidone)
• Electrolyte abnormalities (low potassium or magnesium)
• Hepatic or renal impairment (reduced clearance, so higher levels)

Part 3: How to Start and Dose

The single most important dosing principle: give the whole dose at bedtime. Trazodone's short half-life (about 7 to 8 hours) is long enough to carry a patient through the night and short enough that most of the sedation is spent by morning. Bedtime dosing dramatically improves tolerability compared with divided dosing, even with the standard instant-release tablet, and it is the reason full-dose divided antidepressant regimens fail so often.

Formulations

• Instant-release (generic): use this. Cheap (about $0.03/tablet), flexible, available in 50, 100, 150, and 300 mg. Scored tablets let you fine-tune.
• Extended-release (Oleptro): gone. The XR formulation was discontinued in 2015 and is no longer commercially available. It never delivered on its promise anyway: modest effect size (about 0.28), and daytime somnolence remained common (31% vs 16% placebo). Don't go looking for it.

For Insomnia (the Common Use)

• Start: 25 to 50 mg at bedtime.
• Titrate: increase toward 150 mg qhs over 7 to 10 days as needed for effect.
• Most insomnia patients respond at or below 150 mg qhs; many at 50 to 100 mg.

For Depression (the On-Label Use)

• Antidepressant efficacy generally requires 150 to 400 mg/day (label range extends to a maximum of 600 mg/day).
• Give it all at bedtime and titrate by 50 to 75 mg every few days to weekly, guided by sedation. Divided daytime dosing at these levels is usually intolerable.
• Practical reality: many patients cannot climb past about 150 to 200 mg without unacceptable daytime sedation, which is exactly why trazodone monotherapy for depression so often stalls.

For Other Indications

Part 4: Monitoring

Trazodone is refreshingly low-maintenance. No routine serum levels. No mandatory labs. Monitoring is clinical.

At Each Follow-Up, Ask About and Check

• Next-day sedation / functional impairment: the most common reason to adjust timing or dose.
• Orthostatic symptoms: dizziness, lightheadedness on standing; recheck orthostatic BP early in titration and in the elderly.
• Priapism (men): ask directly; reinforce that a prolonged (over 4 hours) or painful erection is an emergency.
• Emergent dysphoria/anxiety: a new worsening of mood or anxiety, particularly after adding a CYP2D6 inhibitor or in an adolescent, may signal an mCPP surge rather than "trazodone made me depressed" (see Part 7).

ECG: repeat periodically in the higher-risk groups listed in Part 2 (age 65 or older, cardiac disease, CYP3A4 inhibitor co-prescription, electrolyte or hepatic/renal issues).

In dementia populations: track behavioral response and consider periodic MMSE, not because trazodone helps cognition (it doesn't) but to confirm it isn't contributing to decline and to document the target symptoms.

Part 5: Side Effects and How to Manage Them

The governing principle: trazodone's problems are almost all predictable consequences of its receptor pharmacology (H1 blockade for sedation, alpha-1 blockade for orthostasis and priapism), and almost all are managed by lowering the dose, moving it to bedtime, or slowing the titration.

Next-Day Sedation / Daytime Somnolence

The most common complaint (31% vs 16% placebo in the XR trials). Expected, given the H1 antagonism.

• Dose entirely at bedtime, as early in the evening as sleep timing allows.
• Lower the dose, or fine-tune between standard doses (37.5, 75 mg).
• If sedation persists and the patient needs a hypnotic, consider a shorter-acting agent (e.g., zaleplon) instead of pushing trazodone.

Orthostatic Hypotension, Dizziness, Syncope

This is the number-one clinically important adverse effect, driven by alpha-1 blockade. It matters most in the elderly, where it drives falls and fractures.

• Counsel on position changes: sit on the edge of the bed for a minute before standing; rise slowly; hold onto furniture when walking at night.
• Slow the titration and start low.
• Check orthostatic BP at baseline and early titration in at-risk patients.
• Refractory or severe cases: compression stockings or an abdominal binder; ensure adequate hydration.
• Syncope is rare but real; take it seriously in anyone with cardiac disease.

Priapism: Rare, Serious, Warn Everyone

Nausea

Roughly twice the placebo rate. Usually mild. Take with food. Reassure; it typically settles.

Headache

Can occur, and may relate to the mCPP metabolite (which is migraine-provoking). In a patient with an active migraine disorder, be cautious with the "-azodones" (trazodone, nefazodone, vilazodone).

The Pleasant Surprises: What Trazodone Doesn't Cause

Two genuine advantages over most antidepressants, and the reason it earns a place despite the sedation:

• Sexual dysfunction: minimal. A major advantage over SSRIs and SNRIs.
• Weight gain: minimal to none. Another major advantage, notably better than mirtazapine, its closest sedating-antidepressant cousin.

Part 6: Overdose and Toxicity

Trazodone has no boxed warning specific to the drug (it carries the standard antidepressant-class warning about suicidal ideation in patients under 25).

In overdose, trazodone is comparatively benign among antidepressants and far safer than the tricyclics. The picture is dominated by:

• Sedation and CNS depression
• Orthostatic hypotension
• Respiratory depression (dose-dependent; the serious risk)
• Priapism
• QT prolongation at high levels

Management is supportive (airway, fluids for hypotension, cardiac monitoring). There is no specific antidote.

QT Prolongation and Torsades

Trazodone prolongs the QT interval in a dose-dependent fashion, and the risk rises sharply when a CYP3A4 inhibitor pushes levels up, or when it is stacked with other QT-prolonging drugs (methadone, ziprasidone) or electrolyte derangement. This is the reason for the ECG thresholds in Parts 2 and 4. In an otherwise healthy patient at hypnotic doses, clinically meaningful QT effects are uncommon.

A Note on the Suicidality Signal

An observational VA cohort (about 350,000 veterans) found trazodone associated with a roughly 1.5 times higher rate of suicide attempts versus zolpidem. This is almost certainly confounding, not causation: trazodone is preferentially prescribed for nightmares and PTSD, populations with a higher baseline suicide risk, and the analysis didn't control for substance use, impulsivity, or drug interactions. There is no prospective evidence that trazodone causes suicidality, and the current data are insufficient to recommend against its use. Prescribe on the merits, and screen for suicidality as you would with any patient.

Part 7: Drug Interactions: The Two That Matter

Trazodone is a CYP3A4 substrate, and its active metabolite mCPP (m-chlorophenylpiperazine) is cleared by CYP2D6. Both facts generate a clinically important interaction. Master these two and you've mastered trazodone interactions.

1. CYP3A4 Inhibitors: Higher Trazodone Levels

• Culprits: ketoconazole and azole antifungals, ritonavir, clarithromycin/erythromycin, nefazodone, grapefruit; also relevant alongside QT-prolongers like methadone and ziprasidone.
• Effect: more sedation, morning grogginess, and increased QT prolongation/torsades risk.
• Action: reduce the trazodone dose; consider an ECG if the combination is necessary.

2. CYP2D6 Inhibitors: Higher mCPP Levels, the Subtle, Important One

This is the interaction clinicians miss. mCPP is a 5-HT2C agonist that, at stable chronic levels, behaves like a protective serotonin partial agonist, but an abrupt spike is dysphorogenic, anxiogenic, and even hallucinogenic. Block CYP2D6 and mCPP accumulates.

• Culprits: fluoxetine, paroxetine, fluvoxamine, duloxetine, bupropion, sertraline at 150 mg/day or higher.
• What it looks like: a patient (classically an adolescent) develops new dysphoria, anxiety, or self-harm ideation after a 2D6 inhibitor is added. On paper it reads as "trazodone caused depression"; it's actually an mCPP surge.

3. MAOIs: the Counterintuitive One

Package labeling flags MAOIs, and standard teaching demands a 14-day washout. But there is a well-established clinical exception: low-dose trazodone can be used safely with an MAOI as a sleep aid, and as a bridge. One expert group reported about 80 patients treated with trazodone on top of an MAOI safely and effectively, using it to cover the SSRI-washout gap while awaiting MAOI efficacy. It remains serotonergic, so use judgment, but the reflexive "never combine" is not correct for low sleep doses.

4. Other Serotonergic Drugs and CNS Depressants

• Serotonin syndrome risk is low with trazodone relative to other serotonergics, it is rarely the culprit, but the risk is additive with SSRIs/SNRIs, triptans, linezolid, and the like. Monitor when stacking.
• CNS depressants (benzodiazepines, opioids, alcohol): additive sedation and respiratory depression (see Part 6). This is the interaction most likely to actually hurt someone.

Part 8: Special Populations

Elderly (65 and Older)

The population where trazodone demands the most respect, entirely because of orthostasis leading to falls and fractures.

• Start low (25 mg qhs is reasonable), titrate slowly.
• Counsel hard on slow position changes; assess fall risk before prescribing.
• Consider baseline/periodic ECG for QT.
• Upside: it remains genuinely useful and relatively safe for sleep in older adults and in dementia BPSD compared with the alternatives (antipsychotics, benzodiazepines, z-drugs), and it doesn't accumulate the way long-acting benzodiazepines do. A UK dementia cohort (mean age about 79) tolerated 50 to 300 mg/day acceptably for behavioral and sleep symptoms.
• Bottom line: excellent option for the robust older adult with insomnia; think twice in the frail faller.

Pregnancy

Former FDA Category C. Trazodone has a long history of use and no established pattern of major malformation, and is often considered relatively safe, but the human data remain sparse. Individualize, weigh against untreated maternal illness, and coordinate with obstetrics. For pregnancy-related insomnia in particular, non-pharmacologic measures come first.

Lactation

Data are limited. Small amounts pass into breast milk. If used, prefer the lowest effective dose, dose after the last evening feed, and monitor the infant for sedation, in coordination with pediatrics.

Renal Impairment

Trazodone undergoes limited renal elimination. Use with mild caution in severe renal disease; reduced clearance can raise levels (and QT risk), so start low and monitor clinically. No specific dose-reduction table is well established.

Hepatic Impairment

Trazodone is hepatically metabolized (CYP3A4). Use caution in mild-to-moderate disease and avoid or minimize in severe hepatic impairment; reduced clearance raises levels and QT risk. (Its cousin nefazodone carries a true hepatotoxicity warning; trazodone does not, but impaired metabolism is still a reason to go low.)

Children and Adolescents

• No FDA pediatric depression indication; the class suicidality warning applies. Trazodone is used off-label mainly for sleep.
• The mCPP interaction is most dangerous here: adding a CYP2D6 inhibitor can precipitate dysphoria, anxiety, and self-harm ideation. If you use trazodone in an adolescent already on, or about to start, a 2D6 inhibitor, titrate carefully and monitor mood closely.

Part 9: Discontinuation

This is the easy part. As a sedating antidepressant with modest serotonergic reuptake activity and a short half-life, trazodone has a low discontinuation-syndrome risk.

• After short-term or low-dose (hypnotic) use, it can generally be stopped without a formal taper.
• After chronic or higher-dose use, a brief taper over a week or two is reasonable for comfort, but a dramatic protocol is not required.
• Watch for rebound insomnia when stopping a nightly hypnotic: expected, transient, and best pre-empted by tapering the last stretch and reinforcing sleep hygiene rather than immediately re-dosing.

There is no rebound-mania phenomenon and no "loss of future response" concern of the kind that governs lithium discontinuation. Trazodone is forgiving on the way out.

Part 10: Trazodone vs the Alternatives

As a Hypnotic

• vs benzodiazepines: trazodone is non-scheduled, non-addictive, low-tolerance, and improves sleep architecture (increases slow-wave sleep) where benzodiazepines degrade it. Benzodiazepines have faster, more reliable hypnotic potency but carry dependence, tolerance (about 80 to 90%), and cognitive/fall liabilities. Trazodone wins for chronic and comorbid insomnia.
• vs z-drugs (zolpidem, eszopiclone, zaleplon): comparable or better for total sleep time, far cheaper, non-scheduled, much lower tolerance (under 25% vs about 60% for zolpidem), and free of the complex-sleep-behavior boxed warning. The trade-off is more morning sedation. For most patients needing ongoing sleep help, trazodone is the more sensible long-term choice; z-drugs win when a clean, short, as-needed knockout is needed.
• vs ramelteon: ramelteon has no GABA activity and even less behavioral risk, but costs about $3/dose and is a weaker hypnotic; trazodone is preferred on cost and efficacy.
• vs low-dose doxepin (Silenor): for sleep, branded low-dose doxepin offers no clear advantage over generic trazodone at comparable effect.
• vs mirtazapine: similar sleep efficacy, both useful in dementia; trazodone causes less weight gain, while mirtazapine may be preferred when appetite stimulation is desirable.

As an Antidepressant

• Lower efficacy and higher dropout than most modern antidepressants in meta-analysis, but the dropouts are largely sedation-driven, and the drug's absence of weight gain and sexual dysfunction is a real edge for the right patient.
• Best positioned as a second/third-line agent, or as the antidepressant titrated up in a patient who is already taking it for sleep and needs mood coverage: one drug doing two jobs.

Mechanism: The Short Version

Trazodone is a SARI (serotonin antagonist and reuptake inhibitor), a triazolopyridine/phenylpiperazine compound. Its actions are strongly dose-dependent, which is why the same molecule is a hypnotic at 50 mg and an antidepressant at 300 mg:

• 5-HT2A (and 5-HT2C) antagonism: the dominant action at low doses; drives sleep improvement, improves sleep architecture, and underlies the anti-akathisia effect.
• Potent H1 (histamine) antagonism: sedation.
• Alpha-1 adrenergic antagonism: orthostatic hypotension and priapism.
• Serotonin reuptake inhibition: meaningful at the higher antidepressant doses; combined with 5-HT2A blockade, this is the antidepressant mechanism.
• 5-HT1A agonism: contributes to the antidepressant/anxiolytic effect.

The active metabolite mCPP (a 5-HT2C agonist, cleared by CYP2D6) is the pharmacological wildcard: neutral to beneficial at stable chronic levels, but dysphorogenic and anxiogenic when it spikes, the crux of the CYP2D6 interaction. Half-life is about 7 to 8 hours, long enough to maintain sleep across the night, short enough to usually clear by morning.

The Bedside Cheat Sheet

Don't forget: trazodone improves sleep architecture, while benzos and z-drugs degrade it. QT is dose-dependent, which is why the ECG thresholds exist. Discontinuation is easy, with a short half-life, minimal withdrawal, and no rebound mania; just watch for transient rebound insomnia. It is not first-line for depression, but first-rate for insomnia, especially insomnia riding on depression, PTSD, or dementia.